Back to top

Capricor Therapeutics Lawsuit Focuses on Deramiocel Disclosures After CAPR Stock Drops

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is facing a federal securities lawsuit over allegations that investors were not told key facts about sta...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Capricor Therapeutics, Inc. (CAPR)